{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:36:46Z","timestamp":1789875406529,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejphar.2022.175073","type":"journal-article","created":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T21:02:01Z","timestamp":1653685321000},"page":"175073","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["HDAC inhibitor quisinostat prevents estrogen deficiency-induced bone loss by suppressing bone resorption and promoting bone formation in mice"],"prefix":"10.1016","volume":"927","author":[{"given":"Shengxuan","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunmei","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langhui","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0468-6287","authenticated-orcid":false,"given":"Jianquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2022.175073_bib1","doi-asserted-by":"crossref","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","article-title":"JNJ-26481585, a novel \"second-generation\" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity","volume":"15","author":"Arts","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2022.175073_bib2","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1007\/s00198-015-3380-y","article-title":"Severe spontaneous vertebral fractures after denosumab discontinuation: three case reports","volume":"27","author":"Aubry-Rozier","year":"2016","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejphar.2022.175073_bib3","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1111\/j.1600-0765.2011.01392.x","article-title":"Histone deacetylase inhibitors and periodontal bone loss","volume":"46","author":"Cantley","year":"2011","journal-title":"J. Periodontal. Res."},{"key":"10.1016\/j.ejphar.2022.175073_bib4","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.bone.2016.11.028","article-title":"Histone deacetylases (HDAC) in physiological and pathological bone remodelling","volume":"95","author":"Cantley","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2022.175073_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41413-017-0004-5","article-title":"mTOR signaling in skeletal development and disease","volume":"6","author":"Chen","year":"2018","journal-title":"Bone Res"},{"key":"10.1016\/j.ejphar.2022.175073_bib6","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/rheumatology\/keq108","article-title":"Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells","volume":"49","author":"Choo","year":"2010","journal-title":"Rheumatology"},{"key":"10.1016\/j.ejphar.2022.175073_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1525-0016(03)00235-1","article-title":"A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis","volume":"8","author":"Chung","year":"2003","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ejphar.2022.175073_bib8","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1038\/leu.2009.121","article-title":"The effects of JNJ-26481585, a novel hydroxamate-based histone deacetylase inhibitor, on the development of multiple myeloma in the 5T2MM and 5T33MM murine models","volume":"23","author":"Deleu","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2022.175073_bib9","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-08-4472","article-title":"Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2MM murine model of myeloma","volume":"69","author":"Deleu","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2022.175073_bib10","article-title":"Postmenopausal osteoporosis","volume":"2","author":"Eastell","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.ejphar.2022.175073_bib11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1001\/jama.2020.2923","article-title":"Bisphosphonates for postmenopausal osteoporosis","volume":"325","author":"Ensrud","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2022.175073_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24071355","article-title":"Regulation of osteoclast differentiation and skeletal maintenance by histone deacetylases","volume":"24","author":"Faulkner","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejphar.2022.175073_bib13","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2019.01.021","article-title":"Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-kappaB and the downstream c-Fos\/NFATc1 signaling pathways","volume":"848","author":"Guo","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175073_bib14","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","article-title":"Osteoporosis treatment: recent developments and ongoing challenges","volume":"5","author":"Khosla","year":"2017","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2022.175073_bib15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/sj.bjp.0707165","article-title":"Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents","volume":"150","author":"Lin","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175073_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1124\/jpet.115.229328","article-title":"Differential anti-inflammatory activity of HDAC inhibitors in human macrophages and rat arthritis","volume":"356","author":"Lohman","year":"2016","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2022.175073_bib17","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2022.175073_bib18","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1038\/s41467-020-15615-z","article-title":"Selective inhibition of cancer cell self-renewal through a Quisinostat-histone H1.0 axis","volume":"11","author":"Morales Torres","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejphar.2022.175073_bib19","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.ejphar.2022.175073_bib20","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S2213-8587(21)00283-7","article-title":"Revisiting osteoporosis guidelines","volume":"9","author":"Reid","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejphar.2022.175073_bib21","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of Denosumab therapy for osteoporosis: a systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.ejphar.2022.175073_bib22","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jot.2019.03.002","article-title":"Sargassum integerrimum inhibits oestrogen deficiency and hyperlipidaemia-induced bone loss by upregulating nuclear factor (erythroid-derived 2)-like 2 in female rats","volume":"19","author":"Wu","year":"2019","journal-title":"J Orthop Translat"},{"key":"10.1016\/j.ejphar.2022.175073_bib23","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jot.2020.03.001","article-title":"A modified tape transfer approach for rapidly preparing high-quality cryosections of undecalcified adult rodent bones","volume":"26","author":"Yang","year":"2021","journal-title":"J Orthop Translat"},{"issue":"3","key":"10.1016\/j.ejphar.2022.175073_bib24","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1002\/jbmr.4485","article-title":"Hedgehog signaling controls bone homeostasis by regulating osteogenic\/adipogenic fate of skeletal stem\/progenitor cells in mice","volume":"37","author":"Zhang","year":"2021","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejphar.2022.175073_bib25","doi-asserted-by":"crossref","first-page":"6638","DOI":"10.7150\/thno.44793","article-title":"Genetic and pharmacological activation of Hedgehog signaling inhibits osteoclastogenesis and attenuates titanium particle-induced osteolysis partly through suppressing the JNK\/c-Fos-NFATc1 cascade","volume":"10","author":"Zhang","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.ejphar.2022.175073_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174176","article-title":"Inhibition of osteoclastogenesis by histone deacetylase inhibitor Quisinostat protects mice against titanium particle-induced bone loss","volume":"904","author":"Zhang","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2022.175073_bib27","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jot.2019.08.004","article-title":"The efficacy and safety of denosumab in postmenopausal women with osteoporosis previously treated with bisphosphonates: a review","volume":"22","author":"Zhu","year":"2020","journal-title":"J Orthop Translat"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992200334X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992200334X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T23:04:35Z","timestamp":1757977475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992200334X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":27,"alternative-id":["S001429992200334X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175073","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HDAC inhibitor quisinostat prevents estrogen deficiency-induced bone loss by suppressing bone resorption and promoting bone formation in mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2022.175073","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"175073"}}